Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Supplementary cash flow information

v3.19.3.a.u2
Supplementary cash flow information
12 Months Ended
Dec. 31, 2019
Supplementary Cash Flow Information [Abstract]  
Supplementary cash flow information
Supplementary cash flow information
Net change in other operating assets and liabilities

2019
$

 
2018
$

Accounts receivable and accrued interest receivable
(151
)
 
(108
)
Prepaid expenses and deposits
(1,975
)
 
(5,094
)
Clinical trial contract deposits
149

 
90

Accounts payable and accrued liabilities
4,106

 
(888
)

2,129

 
(6,000
)
Interest received
2,619

 
2,148


Cash flows from financing and investing activities:
 
Short term investments

 
Derivative
warrants
December 28, 2016

 
Derivative
warrants
February 14, 2014

 
Common shares

 
Warrants

 
Contributed surplus

Balance at
January 1, 2019
7,889

 
(15,475
)
 
(6,272
)
 
(504,650
)
 

 
(24,690
)
Cash flow - Proceeds from short term investments
(7,884
)
 

 

 

 

 

Cash flow - Net proceeds from commons shares issued pursuant to Public Offering

 

 

 
(179,918
)
 

 

Cash flow - Net proceeds from commons shares issued pursuant to ATM facilities

 

 

 
(43,200
)
 

 

Cash flow - Proceeds from exercise of derivative warrants

 

 

 
(6,989
)
 

 

Cash flow - Proceeds from exercise of options

 

 

 
(13,748
)
 

 

Cash flow - Contingent consideration payments made

 

 

 

 

 
 
Non-cash changes - Recognition of royalty obligation

 

 

 

 

 

Non-cash changes - Conversion to common shares

 
27,598

 
5,920

 
(41,967
)
 

 
8,449

Non-cash changes - Fair value adjustments

 
(41,476
)
 
352

 

 

 

Non-cash changes - Stock based compensation

 

 

 

 

 
(7,414
)
Non-cash changes - Other
(5
)
 

 

 

 

 

Balance at
December 31, 2019

 
(29,353
)
 

 
(790,472
)
 

 
(23,655
)
Balance at
January 1, 2018
7,833

 
(8,948
)
 
(2,845
)
 
(499,200
)
 
(906
)
 
(18,360
)
Cash flow - Purchases
36,084

 

 

 

 

 

Cash flow - Proceeds from short term investment
(36,093
)
 

 

 

 

 

Cash flow - Proceeds from exercise warrants

 

 

 
(3,071
)
 

 

Cash flow - Proceeds from exercise options

 

 

 
(943
)
 

 

Non-cash changes - Conversion to Common Shares

 

 

 
(1,436
)
 
906

 
530

Non-cash changes - Fair value adjustments
 
 
(6,527
)
 
(3,427
)
 

 

 

Non-cash changes - Stock Based Compensation

 

 

 

 

 
(6,860
)
Non-cash changes - Opening adjustment on change in accounting policy
78

 

 

 

 

 

Non-cash changes - Other
(13
)
 

 

 

 

 

Balance at
December 31, 2018
7,889

 
(15,475
)
 
(6,272
)
 
(504,650
)
 

 
(24,690
)